Biocurious: Atomo is girding for the



These ageing rockers haven't lost their punch. Sadly, syphilis hasn't either on its global comeback tour. Pic: Getty Images

More related stories

Despite extensive sexual health campaigns, syphilis is having a moment



sexual health awareness campaigns.

Everything you need to know before the ASX opens

Good morning! Here's everything you need to know before the ASX flings open its doors and begins trading today.

The incidence of the STD is said to have doubled in western countries including the US, the UK, Canada and – yes – Australia.

Possible reasons include 'condom fatigue' and the digital hook-up culture that encourages more bed hopping … not that we're judging anyone.

Others posit that an increasing divorce rate among older couples is to blame, as randy newly emancipated senior singles forget what they learned in year 10 sex ed class.

Yet another theory is the pandemic meant health experts focused on Covid-19 at the expense of routine STD screening.



Stockhead

Syphilis test 'one of many'

Veteran care opens the door for tech

Thrive Tribe is having a crack at making veteran healthcare easier to navigate as government spending on care ramps up.

Enter Atomo Diagnostics (ASX:ATI), which is eyeing syphilis detection as the next cab off the rank for its blood-based, point-of-care testing platforms.

Atomo's tests are based on the company's uniform hardware: Pascal cassettes.

The lateral flow immune assays involve a liquid sample (blood) being

The tests are either a finished product in a nice package, or a naked device to which other assay developers can add their own test strip.

Atomo listed on April 16, 2020, having raised $30 million at 20 cents apiece.

Before you could say cytokine storm, the company sold more than 1.3 million Covid tests before the post-pandemic blues set in.

for HIV, as well as a pregnancy self-test.

Separately, the company holds an exclusive global licence to commercialise a rapid, point-of-care liver function screening test developed by the Burnet Institute.

The assay measures alanine aminotransferase (ALT), a primary blood marker for liver inflammation, injury, and cell damage.

The test targets patients prescribed potentially liver-damaging drugs, as well as the common fatty liver disease.

Atomo also has a partnership with an unnamed UK company, for a Mystery Indication that "addresses a large unmet clinical need in professional settings".

Atomo also provides the h

Febridx bacterial-versus-viral tests, which Lumos is commercialisi

(see below).

My News Feed

Read More



Leaders & Companies

Blood spilt as chair directors ousted at iconic Aussie company



SA News

Mayfair Hotel to be transformed after $75m sale



Business

Digital air traffic control towers not fit for WFH, says Airservices boss

Good Morning George

Recommended based on what you've read



AFL

Crows board member lashes out at 'disgraceful' Nicks report



Local Footy

Why Leongatha's three-time premiership coach called it quits



Eastern

Country power Moe lands Eastern ruckman

Trending now

State Election

They refused to let the state government 'invade' their land. Then the fine arrived



Read More

Royals

King's olive branch to Harry, Meghan shares glimpse of Lilibet's voice



AFL
His coaching future is up in the air, but one thing is certain for Bucks

Puzzles
What fruit is an essential ingredient in banoffee pie?

State Election
Labor ran secret polls – then hijacked a popular project in a stealthy SRL spin job

The Block
Bit's** **t': Wild scandal rocks The Block**

State Election
Bushwhacked: Labor suffers brutal regional poll blow as election looms


Tennis
Fiery tennis star DQ'd after hitting ball into fan's eye

Lifestyle
Tripates How for beloved Play School star

Gold Coast
Agents warn home sellers must slash prices


Changing of the guard

In August Atomo anointed [illegible] ber Dr Cherri Walker as CEO John Kelly who stepped down in August after 15 years at the helm

(With a background in product development, Kelly co-founded Atomo in 2010 because the existing blood [illegible] resembled a clumsy 'chemi[illegible]')

The Boston-based Walker admits Atomo's story hasn't exactly bee[illegible] to date, but the company has a solid platform on which to build a raft of tests.

From now, management's focus turns from building the platform to developing individual test[illegible] current state.

"We really need to figure out how we can jump-start more tests to help continue to layer revenue on revenue on revenue."

Making a diffe[illegible] with HIV tests

Atomo's flagship third generation self-HIV test has been selling str[illegible] 196 chemists here and 73 in New Zealand. The company expects the local pharmacy reach to grow sixfold over the next three years.

Atomo also has had encouraging sales in Africa, but is underpenetrated in Asia Pacific.

The test is not yet approved in the US.

Management is turning its attention to a 'gen 4', professional version.

Chief operating officer Chandra Sukumar notes the company took HIV all the way from development to commercialisation.

"It's been an important part of the company's ethos," she says. "In the early days we were focused on Africa because we really want to make a difference."

Reflecting this, the company has a manufacturing facility and a 22-strong team in Cape Town, South Africa.

"It opens doors for the company if you have manufacturing and infrastructure there."

A Pox on all your houses

The syphilis trial is expected to cover more than 1500 patients, a mix of previously treated and untreated and active subjects.

Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
Follow

Atomo is working with Sydney and Melbourne sexual health clinics. But to achieve the numbers the company is looking at recruiting in Africa, where the disease prevalence is high.

Ultimately, the company strives for local Therapeutic Goods Administration clearance. Beyond the small local market, the agency's imprimatur could open other Asian Pacific and European geographies.

With the trial costed at around US$3-3.5 million – more than Atomo's cash resources – the company plans to partner for the entire trial.

Discussions are at an early stage.

Current assays will determine whether someone has been infected in the past few years.

“You really want to identify people who are actively infected,” Walker says.

“But you also don't want to treat them if they were infected three years ago and they're not actively infected now.

“It’s all about antibiotic stewardship as well.”

While syphilis is a key development priority, Atomo is undertaking early feasibility studies for other indications, including (potentially) HPV and hepatitis B.

Hepatitis makes sense for the portfolio, given it is blood-borne, often sexually transmitted and liver-related.

Keep it simple, stupid

As with any self-test or point-of-care assay, Atomo’s devices need to be foolproof.

The units collect the blood sample volume without air bubbles that might mess up the result.

A built-in safety lancet reduces the risk of needle injury after use.

A storage 'blister' enables a precise quantity of buffer to the test strip. This minimises user error and ensures consistency.

“You just put your finger on it, put the blood into it, and you push the button," Walker says.

Atomo reported revenue of $5.3 million for the year to June 2026, 41% higher. The underlying loss narrowed to $2.06 million from a $3.38m deficit previously.

HIV testing contributed $2.8 million of the turnover, up 21%.

In its early days of US commercialisation, Febridx chipped in $2.2 million, up 209%.

Meanwhile, Chromacare has ordered $170,000 of ferritin tests.

Lumos shines on initial US sales

In the US Lumos sells Febridx via an exclusive distributor deal with Phase Scientific. The compact is worth up to US$317 million in revenue for Lumos over its six-year life.

In August Phase ordered an initial US$767,800 of Febridx tests, funded by a US$5 million milestone payment that Lumos pocketed in March.

“This order comes at an important time as US healthcare providers prepare for the upcoming flu season,” Lumos CEO Doug Ward said at the time.

In September, Lumos reported that Febridx was being used at 215 sites across 26 states. These clinics account for 900,000 to 1.2 million acute respiratory infections (ARIs) annually.

Potential clients accounting for a further 405 sites and 1.6-2.2 million annual ARI visits are appraising the test.

Following an initial pilot, foundation customer WellStreet deploys the test at 44 urgent care clinics. Lumos cites a “pathway” to more than 165 WellStreet sites.

Walker says Atomo wants to be the best partner it can for all its allegiances, including the Lumos tie-up.

“It’s great we can participate in the success that Lumos is having."

Lumos and Atomo don’t disclose the terms of the supply deal. Suffice to say, ‘own’ product margins usually are more attractive than ‘white label’ deals.

Having said that, Atomo's fortunes are likely to track those of Lumos in the foreseeable future.

Developing tests everyone ‘knows and loves’

Walker was a life sciences analyst at Deutsche, covering large global companies.

She then filled corporate roles, including CEO of antibody specialist Zeta Corporation and head of early-stage diagnostics company Rhinostics Inc.

“It's very interesting to be on the board of a small ASX-listed company,” she says.

“Like everything in life, it has some real positives and some challenges.”

While other life science companies say it’s a hard slog, Walker says the local market is OK for raising capital.

While she won’t be drawn on Atomo’s plans, a $3.7 million cash balance means an equity raising is inevitable.

Barring a Prince Charming partner, of course ...

On the flipside, the local sector is dominated by retail investors, rather than patient institutions.

“There’s an education gap between the big funds that really understand the market dynamics and retail investors, who just can't understand it to the same level," Walker says.

“But hopefully we can keep them interested”.

On that note, Atomo promises a solid pipeline of news flow. Things to watch out for include syphilis trial progress, Febridx sales volumes in the US flu season and the company's efforts to reduce cash outflows.

Ultimately, additional Atomo assays will move the needle the most.

Walker says Atomo’s “easy and repeatable” tech inspired her to join the company in the first place.

“We would like to have a whole set of the same devices that everyone knows and loves and are easy to use.”

Originally published as Biocurious: Atomo is girding for the STD ‘comeback tour’ no-one wants to see

Membership

Subscription packages
Group/Corporate subscriptions
Herald Sun app
Today's Paper
Newsletters

About Us

About us
Meet the team
Job Opportunities
Code of conduct
Subscription FAQs
Subscription terms
Financial Hardship Policy

Contact Us

Help & support
Story Tips
FAQs
Standards of practice
Letter to the Editor
Licensing & Reprints
Advertise with us

Our News Network

The Daily Telegraph
The Courier Mail
The Advertiser
news.com.au
The Australian
The Mercury
Geelong Advertiser
The Cairns Post
Gold Coast Bulletin
Townsville Bulletin
The Chronicle
NT News
The Weekly Times
CODE Sports

Our Partners

Buy Search Sell Classifieds
Find Your Local
Foxsports
Foxtel
Hipages
Kayo
My Tributes
Punters
odds.com.au
racenet.com.au
News24 Australia
Coupons

Our Apps

Download on the App Store
GET IT ON Google Play

A NOTE ABOUT RELEVANT CONTENT: We collect information about the content (including ads) you use across this site and use it to make both advertising and content more relevant to you on our network and other sites. Find out more about our policy and your choices, including how to opt-out of targeted advertising based on your browsing behaviour on our network.Sometimes our articles will try to help you find the right product at the right price. We may receive payment from third parties for publishing this content or when you make a purchase through the links on our sites.

Nationwide News Pty Ltd © 2026. All times AEDT (GMT +11). Powered by WordPress.com VIP

Privacy policy Relevant ads opt-out Cookie policy Terms of use